BioLineRx, Ltd. - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 63 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

BioLineRx, Ltd. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'BioLineRx, Ltd. - Product Pipeline Review - 2014', provides an overview of the BioLineRx, Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of BioLineRx, Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of BioLineRx, Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of BioLineRx, Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the BioLineRx, Ltd.'s pipeline products

Reasons to buy

- Evaluate BioLineRx, Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of BioLineRx, Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the BioLineRx, Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of BioLineRx, Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of BioLineRx, Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of BioLineRx, Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
BioLineRx, Ltd. Snapshot 6
BioLineRx, Ltd. Overview 6
Key Information 6
Key Facts 6
BioLineRx, Ltd. - Research and Development Overview 7
Key Therapeutic Areas 7
BioLineRx, Ltd. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Combination Treatment Modalities 13
BioLineRx, Ltd. - Pipeline Products Glance 14
BioLineRx, Ltd. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
BioLineRx, Ltd. - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
BioLineRx, Ltd. - Drug Profiles 18
BL-7040 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
BL-8040 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
(ribavirin + hydroxychloroquine) 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
BL-7010 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
BL-4010 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
BL-5030 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
BL-5040 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
BL-8030 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
BL-9010 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
BL-9020 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
CGEN-855-A 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CGEN-855-B 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
CGEN-856 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
EDP-25 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
EDP-32 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
EDP-34 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
BioLineRx, Ltd. - Pipeline Analysis 40
BioLineRx, Ltd. - Pipeline Products by Target 40
BioLineRx, Ltd. - Pipeline Products by Route of Administration 42
BioLineRx, Ltd. - Pipeline Products by Molecule Type 43
BioLineRx, Ltd. - Pipeline Products by Mechanism of Action 44
BioLineRx, Ltd. - Recent Pipeline Updates 46
BioLineRx, Ltd. - Dormant Projects 55
BioLineRx, Ltd. - Discontinued Pipeline Products 57
Discontinued Pipeline Product Profiles 57
BL-1050 57
BL-1020 57
BL-2030 57
BL-4040 58
BL-4060 58
BL-5020 58
BL-6010 58
BL-6020 58
BL-6031 58
BL-6040 58
BL-7020 58
BL-7030 59
BL-7040 59
BL-7050 59
BL-8010 59
BioLineRx, Ltd. - Company Statement 60
BioLineRx, Ltd. - Locations And Subsidiaries 61
Head Office 61
Other Locations & Subsidiaries 61
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 63
Disclaimer 63

List of Tables
BioLineRx, Ltd., Key Information 6
BioLineRx, Ltd., Key Facts 6
BioLineRx, Ltd. - Pipeline by Indication, 2014 9
BioLineRx, Ltd. - Pipeline by Stage of Development, 2014 11
BioLineRx, Ltd. - Monotherapy Products in Pipeline, 2014 12
BioLineRx, Ltd. - Combination Treatment Modalities in Pipeline, 2014 13
BioLineRx, Ltd. - Phase II, 2014 14
BioLineRx, Ltd. - Phase I, 2014 15
BioLineRx, Ltd. - Preclinical, 2014 16
BioLineRx, Ltd. - Discovery, 2014 17
BioLineRx, Ltd. - Pipeline by Target, 2014 41
BioLineRx, Ltd. - Pipeline by Route of Administration, 2014 42
BioLineRx, Ltd. - Pipeline by Molecule Type, 2014 43
BioLineRx, Ltd. - Pipeline Products by Mechanism of Action, 2014 45
BioLineRx, Ltd. - Recent Pipeline Updates, 2014 46
BioLineRx, Ltd. - Dormant Developmental Projects,2014 55
BioLineRx, Ltd. - Discontinued Pipeline Products, 2014 57
BioLineRx, Ltd., Subsidiaries 61